Table 3.
Main anti-angiogenic vaccination approaches currently undergoing clinical trials.
| Antigens | Vaccine Type | Tumor Type | Phase | REF/NIH N. |
|---|---|---|---|---|
| VEGF-A | Recombinant human VEGF-A-121 isoform |
Advanced solid tumors | I | Gavilondo 2014 [108] |
| VEGFRs | VEGFR2-169 peptide | Pancreatic cancer | I | Miyazawa 2010 [101] |
| VEGFR1-1084 and VEGFR2-169 peptides | I/II | NCT00655785 | ||
| VEGFR1-A2-770 peptide | I/II | NCT00683085 | ||
| VEGFR2-169 peptide | Advanced solid tumors | I | Okamoto 2012 [102] | |
| VEGFR1-1084 peptide | I | Hayashi 2013 [103] | ||
| VEGFR2, VEGFR1, URLC10, TTK, CDCA1 multipeptide | Non small cell lung cancer | I | Suzuki 2013 [104] | |
| Survivin | hTERT/survivin/CMV multipeptide | Breast cancer | I | NCT01660529 |
| Survivin long peptide | Neuroendocrine tumors | I | NCT03879694 | |
| Salmonella-based Survivin peptide | Multiple myeloma | I/II | NCT03762291 | |
| EGF | Recombinant Human EGF-rP64K/Montanide ISA 51 peptide | Non-small cell lung cancer | II | Garcia 2008 [105] |
| II/III | NCT00516685 | |||
| III | NCT02187367 | |||
| III | NCT01444118 | |||
| Non-small cell lung cancer, squamous head and neck cancer |
I/II | NCT02955290 |